# Kasim Kutay

> Kasim Kutay is a Series A investor at Novo Holdings (London) backing Biotechnology and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Novo Holdings](https://shizune.co/investors/profile/novo-a-s)
- Location: London, United Kingdom
- Total investments: 2
- Last investment: Jul 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kasim-kutay/

Kasim Kutay is a Series A investor at Novo Holdings in London focused on Biotechnology and Health Care. Kasim Kutay

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series C | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Singapore | 1 | 50% |
| Switzerland | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Asceneuron | Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression. | $100M | Series C | Jul 16, 2024 |  |
| Esco Lifesciences | Esco Lifesciences Group provides enabling technologies, products, and services for the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing. | $200M | Series A | May 26, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 2 deals together
- [China Investment Corporation](https://shizune.co/investors/profile/china-investment-corporation) — VC Fund, 1 deal together
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 1 deal together
- [GlaxoSmithKline](https://shizune.co/investors/profile/glaxosmithkline) — VC Fund, 1 deal together
- [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 1 deal together
- [K3 Ventures](https://shizune.co/investors/profile/k3-ventures) — VC Fund, 1 deal together

## About Novo Holdings

VC Fund · Hellerup, Denmark

Novo Holdings is a holding and investment firm that manages the assets of the Novo Nordisk Foundation. It is a life science investor with a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments.

5 contacts available at Novo Holdings.

| Name | Title | Profile |
| --- | --- | --- |
| Emmanuelle Coutanceau | Partner Novo Seeds | https://shizune.co/investors/profile/emmanuelle-coutanceau |
| Thomas Dyrberg | Partner | https://shizune.co/investors/profile/thomas-dyrberg |
| Thomas Grotkjær | Investor & Principal | https://shizune.co/investors/profile/thomas-grotkj%C3%A6r |
| Abhijeet Lele | Senior Partner and Head of US Principal Investments | https://shizune.co/investors/profile/abhijeet-lele |
| Christopher Shen | Partner | https://shizune.co/investors/profile/christopher-shen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kasim Kutay invest in?

Kasim Kutay invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 2 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kasim Kutay last invest?

The most recent investment recorded for Kasim Kutay closed in Jul 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co